CEL-SCI study in Oral Oncology flags low PD-L1, N0 oral cancer patients for Multikine survival benefit

Reuters2026/08/04 12:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

CEL-SCI published peer-reviewed results in Oral Oncology from its IT-MATTERS trial; results were already presented in the journal publication.
Study supports using low or zero PD-L1 expression and no lymph node involvement to identify oral cancer patients most likely to benefit from Multikine.
Biomarker-selected patients treated with Multikine before surgery showed better survival outcomes than standard care alone, supporting a differentiated positioning versus checkpoint inhibitors.
Enrollment is being prepared for a 212-patient global confirmatory registration study in the same biomarker-defined population to validate the earlier survival benefit.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CEL-SCI Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202608040800BIZWIRE_USPR_____20260804_BW733241) on August 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

CEL-SCI study in Oral Oncology flags low PD-L1, N0 oral cancer patients for Multikine survival benefit

You may also like

Crypto prices